Kane Biotech Inc. (KNE.V)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Marc Edwards | President, CEO & Director | 268.5k | -- | -- |
Mr. Ray Dupuis | Chief Financial Officer | 161.69k | -- | -- |
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC | Executive Chairman & Member of Scientific Advisory Board | -- | -- | 1965 |
Dr. Gregory S. Schultz Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | -- | -- | 1950 |
Lorne Gorber | Investor Relations | -- | -- | -- |
Ms. Wendy Nachtigall | Director of Marketing | -- | -- | -- |
Ms. Lori Christofalos | Chief Quality Officer | -- | -- | -- |
Nicole Sendey | Investor Relations Adviser | -- | -- | -- |
Kane Biotech Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Corporate Governance
Upcoming Events
November 26, 2024 at 10:59 AM UTC - December 2, 2024 at 12:00 PM UTC
Kane Biotech Inc. Earnings Date
Recent Events
March 13, 2017 at 12:00 AM UTC
Dividend Date